These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 38073038)

  • 1. Empagliflozin in Heart Failure: Regional Nephron Sodium Handling Effects.
    Rao VS; Ivey-Miranda JB; Cox ZL; Moreno-Villagomez J; Maulion C; Bellumkonda L; Chang J; Field MP; Wiederin DR; Butler J; Collins SP; Turner JM; Wilson FP; Inzucchi SE; Wilcox CS; Ellison DH; Testani JM
    J Am Soc Nephrol; 2024 Feb; 35(2):189-201. PubMed ID: 38073038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects.
    Griffin M; Rao VS; Ivey-Miranda J; Fleming J; Mahoney D; Maulion C; Suda N; Siwakoti K; Ahmad T; Jacoby D; Riello R; Bellumkonda L; Cox Z; Collins S; Jeon S; Turner JM; Wilson FP; Butler J; Inzucchi SE; Testani JM
    Circulation; 2020 Sep; 142(11):1028-1039. PubMed ID: 32410463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Similarities and distinctions between acetazolamide and sodium-glucose cotransporter 2 inhibitors in patients with acute heart failure: Key insights into ADVOR and EMPULSE.
    Packer M; Butler J
    Eur J Heart Fail; 2023 Sep; 25(9):1537-1543. PubMed ID: 37403655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
    Mordi NA; Mordi IR; Singh JS; McCrimmon RJ; Struthers AD; Lang CC
    Circulation; 2020 Nov; 142(18):1713-1724. PubMed ID: 32865004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compensatory Distal Reabsorption Drives Diuretic Resistance in Human Heart Failure.
    Rao VS; Planavsky N; Hanberg JS; Ahmad T; Brisco-Bacik MA; Wilson FP; Jacoby D; Chen M; Tang WHW; Cherney DZI; Ellison DH; Testani JM
    J Am Soc Nephrol; 2017 Nov; 28(11):3414-3424. PubMed ID: 28739647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal upregulation of NCC counteracts empagliflozin-mediated NHE3 inhibition in normotensive but not in hypertensive male rat.
    Castro PC; Santos-Rios TM; Martins FL; Crajoinas RO; Caetano MV; Lessa LMA; Luchi WM; McCormick JA; Girardi ACC
    Am J Physiol Cell Physiol; 2024 Jun; 326(6):C1573-C1589. PubMed ID: 38557357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute and Chronic Effects of SGLT2 Inhibitor Empagliflozin on Renal Oxygenation and Blood Pressure Control in Nondiabetic Normotensive Subjects: A Randomized, Placebo-Controlled Trial.
    Zanchi A; Burnier M; Muller ME; Ghajarzadeh-Wurzner A; Maillard M; Loncle N; Milani B; Dufour N; Bonny O; Pruijm M
    J Am Heart Assoc; 2020 Jul; 9(13):e016173. PubMed ID: 32567439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A role for tubular Na
    Onishi A; Fu Y; Patel R; Darshi M; Crespo-Masip M; Huang W; Song P; Freeman B; Kim YC; Soleimani M; Sharma K; Thomson SC; Vallon V
    Am J Physiol Renal Physiol; 2020 Oct; 319(4):F712-F728. PubMed ID: 32893663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial.
    Mordi NA; Mordi IR; Singh JS; Baig F; Choy AM; McCrimmon RJ; Struthers AD; Lang CC
    BMJ Open; 2017 Oct; 7(10):e018097. PubMed ID: 29042392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure.
    Boorsma EM; Beusekamp JC; Ter Maaten JM; Figarska SM; Danser AHJ; van Veldhuisen DJ; van der Meer P; Heerspink HJL; Damman K; Voors AA
    Eur J Heart Fail; 2021 Jan; 23(1):68-78. PubMed ID: 33251643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF).
    Schulze PC; Bogoviku J; Westphal J; Aftanski P; Haertel F; Grund S; von Haehling S; Schumacher U; Möbius-Winkler S; Busch M
    Circulation; 2022 Jul; 146(4):289-298. PubMed ID: 35766022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
    Brady JA; Hallow KM
    J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of lithium clearance as a marker of proximal tubule sodium handling.
    Koomans HA; Boer WH; Dorhout Mees EJ
    Kidney Int; 1989 Jul; 36(1):2-12. PubMed ID: 2681925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action.
    Packer M; Anker SD; Butler J; Filippatos G; Zannad F
    JAMA Cardiol; 2017 Sep; 2(9):1025-1029. PubMed ID: 28768320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial.
    Nassif ME; Qintar M; Windsor SL; Jermyn R; Shavelle DM; Tang F; Lamba S; Bhatt K; Brush J; Civitello A; Gordon R; Jonsson O; Lampert B; Pelzel J; Kosiborod MN
    Circulation; 2021 Apr; 143(17):1673-1686. PubMed ID: 33550815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT2-independent effects of canagliflozin on NHE3 and mitochondrial complex I activity inhibit proximal tubule fluid transport and albumin uptake.
    Albalawy WN; Youm EB; Shipman KE; Trull KJ; Baty CJ; Long KR; Rbaibi Y; Wang XP; Fagunloye OG; White KA; Jurczak MJ; Kashlan OB; Weisz OA
    Am J Physiol Renal Physiol; 2024 Jun; 326(6):F1041-F1053. PubMed ID: 38660713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
    Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
    Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical Analysis of the Effects of SGLT2 Inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and Their Role in Influencing Heart Failure Outcomes.
    Packer M; Wilcox CS; Testani JM
    Circulation; 2023 Jul; 148(4):354-372. PubMed ID: 37486998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Empagliflozin: current indications and aspects for daily clinical practice].
    Iacoviello M; Aspromonte N
    G Ital Cardiol (Rome); 2023 Dec; 24(12 Suppl 3):3S-12S. PubMed ID: 38226446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
    Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N
    Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.